Overton's nomination withdrawal means no clear end for FDA leadership vacuum
The White House's abrupt withdrawal of Heidi Overton as President Trump's nominee to lead the Food and Drug Administration (FDA) means the agency will remain without stable leadership six months after the former commissioner resigned, leaving industry observers anxious. The Trump administration's last-minute pulling of Overton's nomination caught senators by surprise this week. Sen. Bill Cassidy (R-La.), chair of the Senate Health,...



